Ovarian cancer, labeled by the medical society as the deadliest form of gynecologic cancer, was presented with a rather optimistic prospect in March this
year. Studies on an experimental vaccine and the drug Avastin (already on the market) have suggested that both may help slow down late-stage ovarian
cancer. The findings were presented at the Society of Gynecologic Oncology in Chicago in April 2015.
Researchers found that including the vaccine in the standard treatment of advanced-stage ovarian cancer in women forestalled recurrence. The FANG vaccine
is a type of immunotherapy for ovarian cancer. The other study showed that administering Avastin after both surgery and chemotherapy stalled the
progression of the cancer, compared with surgery and chemotherapy alone.
As with any experimental therapy, the long-term effectiveness and safety of these two therapies are yet to be ascertained. However, the point to note is
that the developmental pipeline for the ovarian cancer therapeutics market is teeming with
possibilities and this could be the driving force of a currently restrained market, especially in Asia Pacific.
Even though late-stage drugs for ovarian cancer have displayed poor efficacy, the positive news is that there have been minimal but steady improvements
during progression-free survival. Investigational drugs such as trebananib and olaparib have also demonstrated promising results, indicating a possible
approval over the next few years. However, this too is likely to be marred by low market penetration owing to premium prices and minimal therapeutic
The major challenge that the ovarian cancer therapeutics market faces is trying to halt the rapid progression of the disease, and that too by means of
personalized and targeted therapy. A new set of drugs being developed by Constellation Pharmaceuticals and Epizyme is hoping to tackle this exact
The American Cancer Society indicates that ovarian cancer is the fifth most common cause of death by cancer among women, with one in every 75 women at the
risk of getting ovarian cancer. Compared to Europe and North America, Asia has a relatively lower incidence of ovarian cancer. In 2015, around 21,290 women
in the U.S. alone will be diagnosed with ovarian cancer, close to 14,200 of which will die from the disease this year.
Scientists all over the world continue to study the genes that are responsible for familial ovarian cancer and increased research activities in this field
are not only expected to yield new drugs for the prevention and treatment of ovarian cancer but are also estimated to boost the growth of the ovarian
cancer therapeutics market.
A study conducted by GBI Research on the ovarian cancer therapeutics market maps the growth and development of the market in Asia Pacific. The report
forecasts that the market is likely to grow at a slow rate of 5.1%, reaching a value of US$417.6 million by 2020. The Asia Pacific market for ovarian
cancer therapeutics, according to GBI Research, is primarily driven by inflation and the rising prevalence of ovarian cancer.
Even though targeted therapies for the treatment of ovarian cancer lag significantly behind other types of cancers, continued interest in novel molecular
targets could help put the ovarian cancer therapeutics market on track.
Browse the full Global Ovarian Cancer Therapeutics Market report at http://www.mrrse.com/ovarian-cancer-therapeutics